**Appendix Table D50. Strength of evidence about treatment discontinuation due to adverse effects with antiepileptic drugs for migraine prevention in children**

| **Active drug** | **Dose** | **Rate with drug, % [placebo]** | **RCTs** | **Children** | **Directness** | **Risk of bias** | **Consistency** | **Precision** | **Dose response** | **Strength of evidence** | **Conclusion** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Divalproex sodiumU.S. Food and Drug Administration6Apostol, 20085 | 1000mg | 9.3[1.4] | 1 | 148 | Yes | Low | Yes | No | Yes | Low | Divalproex sodium 1000mg resulted in greater treatment discontinuation rates vs. placebo |
| 250mg | 2.4[1.4] | 1 | 156 | Yes | Low | Yes | No | Yes | Low | Divalproex sodium 250mg did not result in greater treatment discontinuation rates vs. placebo |
| TopiramateLewis, 20097Pandina, 201017,Winner, 20058 | 50-200mg | 7.1[3.4] | 2 | 265 | Yes | Medium | Yes | No | No | Low | Topiramate did not result in greater treatment discontinuation rates vs. placebo |